Gene therapy needs robust synthetic nonviral platform technologies.
about
Tris(benzimidazolyl)amine-Cu(II) coordination units bridged by carboxylates: structures and DNA-condensing property.Lipid-based nanoparticles in cancer diagnosis and therapy.Multivalent glycocalixarenes for recognition of biological macromolecules: glycocalyx mimics capable of multitasking.Nanomedicine therapeutics and diagnostics are the goal.Ruthenium(II) polypyridyl complexes as carriers for DNA delivery.
P2860
Gene therapy needs robust synthetic nonviral platform technologies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Gene therapy needs robust synthetic nonviral platform technologies.
@en
Gene therapy needs robust synthetic nonviral platform technologies.
@nl
type
label
Gene therapy needs robust synthetic nonviral platform technologies.
@en
Gene therapy needs robust synthetic nonviral platform technologies.
@nl
prefLabel
Gene therapy needs robust synthetic nonviral platform technologies.
@en
Gene therapy needs robust synthetic nonviral platform technologies.
@nl
P2860
P356
P1433
P1476
Gene therapy needs robust synthetic nonviral platform technologies.
@en
P2093
Andrew D Miller
P2860
P356
10.1002/CBIC.200300766
P577
2004-01-01T00:00:00Z